MinervaX is developing a novel vaccine for Group B Streptococcus (GBS) for maternal immunization. GBS infection is a worldwide unmet medical need, causing up to 50% of serious infections in newborns in the first 3 months of life, leading to severe morbidity with life-long disabilities and mortality. To protect infants from GBS induced diseases, a maternal vaccine given to pregnant women is the only long-term viable option, which is recognized and prioritized by WHO, CDC, NIH, Public Health England, and the Gates Foundation. However, no approved vaccine exists, as of yet. MinervaX’ GBS vaccine candidate is currently in clinical phase 2 development.